Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147,678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate.
Versteeg L, Adhikari R, Robinson G, Lee J, Wei J, Islam N, Keegan B, Russell WK, Poveda C, Villar MJ, Jones K, Bottazzi ME, Hotez P, Tijhaar E, Pollet J. Versteeg L, et al. Among authors: lee j. PLoS Pathog. 2024 Dec 18;20(12):e1012764. doi: 10.1371/journal.ppat.1012764. eCollection 2024 Dec. PLoS Pathog. 2024. PMID: 39693359 Free PMC article.
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate.
Chen WH, Wei J, Kundu RT, Adhikari R, Liu Z, Lee J, Versteeg L, Poveda C, Keegan B, Villar MJ, de Araujo Leao AC, Rivera JA, Gillespie PM, Pollet J, Strych U, Zhan B, Hotez PJ, Bottazzi ME. Chen WH, et al. Among authors: lee j. Biochim Biophys Acta Gen Subj. 2021 Jun;1865(6):129893. doi: 10.1016/j.bbagen.2021.129893. Epub 2021 Mar 14. Biochim Biophys Acta Gen Subj. 2021. PMID: 33731300 Free PMC article.
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice.
Pollet J, Chen WH, Versteeg L, Keegan B, Zhan B, Wei J, Liu Z, Lee J, Kundu R, Adhikari R, Poveda C, Villar MJ, de Araujo Leao AC, Altieri Rivera J, Momin Z, Gillespie PM, Kimata JT, Strych U, Hotez PJ, Bottazzi ME. Pollet J, et al. Among authors: lee j. Hum Vaccin Immunother. 2021 Aug 3;17(8):2356-2366. doi: 10.1080/21645515.2021.1901545. Epub 2021 Apr 13. Hum Vaccin Immunother. 2021. PMID: 33847226 Free PMC article.
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate.
Chen WH, Pollet J, Strych U, Lee J, Liu Z, Kundu RT, Versteeg L, Villar MJ, Adhikari R, Wei J, Poveda C, Keegan B, Bailey AO, Chen YL, Gillespie PM, Kimata JT, Zhan B, Hotez PJ, Bottazzi ME. Chen WH, et al. Among authors: lee j. Protein Expr Purif. 2022 Feb;190:106003. doi: 10.1016/j.pep.2021.106003. Epub 2021 Oct 21. Protein Expr Purif. 2022. PMID: 34688919 Free PMC article.
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J, Strych U, Chen WH, Versteeg L, Keegan B, Zhan B, Wei J, Liu Z, Lee J, Kundu R, Adhikari R, Poveda C, Jose Villar M, Rani Thimmiraju S, Lopez B, Gillespie PM, Ronca S, Kimata JT, Reers M, Paradkar V, Hotez PJ, Elena Bottazzi M. Pollet J, et al. Among authors: lee j. Vaccine. 2022 Jun 9;40(26):3655-3663. doi: 10.1016/j.vaccine.2022.05.007. Epub 2022 May 8. Vaccine. 2022. PMID: 35568591 Free PMC article.
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access.
Hotez PJ, Adhikari R, Chen WH, Chen YL, Gillespie P, Islam NY, Keegan B, Tyagi Kundu R, Lee J, Liu Z, Kimata JT, Oezguen N, Pollet J, Poveda C, Razavi K, Ronca SE, Strych U, Thimmiraju SR, Versteeg L, Villar-Mondragon MJ, Wei J, Zhan B, Bottazzi ME. Hotez PJ, et al. Among authors: lee j. Expert Rev Vaccines. 2023 Jan-Dec;22(1):495-500. doi: 10.1080/14760584.2023.2217917. Expert Rev Vaccines. 2023. PMID: 37252854 Free article.
A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
Thimmiraju SR, Adhikari R, Villar MJ, Lee J, Liu Z, Kundu R, Chen YL, Sharma S, Ghei K, Keegan B, Versteeg L, Gillespie PM, Ciciriello A, Islam NY, Poveda C, Uzcategui N, Chen WH, Kimata JT, Zhan B, Strych U, Bottazzi ME, Hotez PJ, Pollet J. Thimmiraju SR, et al. Among authors: lee j. Vaccines (Basel). 2023 Oct 1;11(10):1557. doi: 10.3390/vaccines11101557. Vaccines (Basel). 2023. PMID: 37896960 Free PMC article.
The zebrafish as a potential model for vaccine and adjuvant development.
Hotez PJ, Bottazzi ME, Islam NY, Lee J, Pollet J, Poveda C, Strych U, Thimmiraju SR, Uzcategui NL, Versteeg L, Gorelick D. Hotez PJ, et al. Among authors: lee j. Expert Rev Vaccines. 2024 Jan-Dec;23(1):535-545. doi: 10.1080/14760584.2024.2345685. Epub 2024 May 9. Expert Rev Vaccines. 2024. PMID: 38664959 Free article. Review.
A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses.
Thimmiraju SR, Adhikari R, Redd JR, Villar MJ, Lee J, Liu Z, Chen YL, Sharma S, Kaur A, Uzcategui NL, Ronca SE, Chen WH, Kimata JT, Zhan B, Strych U, Bottazzi ME, Hotez PJ, Pollet J. Thimmiraju SR, et al. Among authors: lee j. NPJ Vaccines. 2024 Jul 22;9(1):132. doi: 10.1038/s41541-024-00924-x. NPJ Vaccines. 2024. PMID: 39034332 Free PMC article.
147,678 results
You have reached the last available page of results. Please see the User Guide for more information.